

**Suppl. Table 3.** Sensitivity of UKF-NB-3 sub-lines adapted to cytotoxic drugs (UKF-NB-3<sup>r</sup>CDDP<sup>1000</sup>, cisplatin; UKF-NB-3<sup>r</sup>DOX<sup>20</sup>, doxorubicin; UKF-NB-3<sup>r</sup>MEL<sup>2000</sup>, melphalan; UKF-NB-3<sup>r</sup>VCR<sup>10</sup>, vincristine) to nutlin-3, RITA, vincristine, and cisplatin (indicated by MTT assay after 5 day incubation).

Cell line	p53 status	Concentrations that decrease cell viability by 50% (IC <sub>50</sub> )			
		RITA (μM)	nutlin-3 (μM)	vincristine (ng/mL)	cisplatin (ng/mL)
UKF-NB-3	wt <sup>1</sup>	0.10±0.03	1.53±0.30	0.20±0.04	99.8±24.1
UKF-NB-3 <sup>r</sup> CDDP <sup>1000</sup>	wt	0.12±0.02	1.65±0.25	0.69±0.05	994.8±89.6
UKF-NB-3 <sup>r</sup> DOX <sup>20</sup>	wt	0.39±0.09	2.96±0.46	44.9±5.48	251.2±35.7
UKF-NB-3 <sup>r</sup> MEL <sup>2000</sup>	wt	0.28±0.06	1.68±0.30	0.62±0.09	613.4±34.4
UKF-NB-3 <sup>r</sup> VCR <sup>10</sup>	C135F <sup>1,2,3</sup>	0.55±0.17	44.6±10.5	87.72±12.8	600.98±51.0

<sup>1</sup> wild-type; <sup>2</sup> type of mutation; <sup>3</sup> homozygote